Estimating Stem Volume Using QuickBird Imagery and Allometric Relationships for Open Populus xiaohei Plantations

There has been a great deal of interest in studying the crown of trees using remote sensing data.In this study,crownwidth was extracted from high-resolution QuickBird images for open Populus xiaohei plantations.Regression modelsfor predicting the individual stem volumes of Populus xiaohei were established using extracted crown width,as well asestimated tree parameters(i.e.diameter at breast height[DBH]and tree height)as predictors.Our results indicated thatcrown width could be accurately extracted from QuickBird images using a multi-scale segmentation approach with a meanrelative error of 5.74%,especially for wide-spacing stands.Using either extracted crown width alone or with estimatedDBH and tree height can successfully estimate individual stem volume of Populus xiaohei with the R~2 value ranging from0.87 to 0.92 depending on different model forms.In particular,the two second-order polynomial models(model2 andmodel 6),based on QuickBird image-derived crown widths and estimated DBH and tree heights,respectively,were the bestat describing the relationship between stem volume and tree characteristics.     

SO2熏气对油桐叶片细胞膜脂组成和叶绿体超微结构的影响

经SO2熏气处理的油桐叶片电导率增加,叶片中脂质过氧化作用增强,总类脂、极性脂、非极性脂、糖脂含量下降,磷脂含量稍有增加;极性脂和非极性脂中不饱和脂肪酸C18:3含量、C18:3/IUFA、不饱和指标UFA和IUFA值下降,叶绿体结构受到破坏,片层结构模糊不清;随着熏气时间的延长叶绿体中的淀粉颗粒增大,脂滴变小.     

Arsenic trioxide promotes mitochondrial DNA mutation and cell apoptosis in primary APL cells and NB4 cell lines

This study aimed to investigate the effects of arsenic trioxide(As2O3) on the mitochondrial DNA(mtDNA) of acute promyelocytic leukemia(APL) cells.The NB4 cell line was treated with 2.0 μmol/L As2O3 in vitro,and the primary APL cells were treated with 2.0 μmol/L As2O3 in vitro and 0.16 mg kg-1 d-1 As2O3 in vivo.The mitochondrial DNA of all the cells above was amplified by PCR,directly sequenced and analyzed by Sequence Navigatore and Factura software.The apoptosis rates were assayed by flow cytometry.Mitochondrial DNA mutation in the D-loop region was found in NB4 and APL cells before As2O3 use,but the mutation spots were remarkably increased after As2O3 treatment,which was positively correlated to the rates of cellular apoptosis,the correlation coefficient:rNB4-As2O3=0.973818,and rAPL-As2O3=0.934703.The mutation types include transition,transversion,codon insertion or deletion,and the mutation spots in all samples were not constant and regular.It is revealed that As2O3 aggravates mtDNA mutation in the D-loop region of acute promyelocytic leukemia cells both in vitro and in vivo.Mitochondrial DNA might be one of the targets of As2O3 in APL treatment.     

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

Elsewhere, we reported the safety and efficacy results of a multicenter phase 3 trial of recombinant human alpha -galactosidase A (rh-alpha GalA) replacement in patients with Fabry disease. All 58 patients who were enrolled in the 20-wk phase 3 double-blind, randomized, and placebo-controlled study received subsequently 1 mg/kg of rh-alpha GalA (agalsidase beta, Fabrazyme, Genzyme Corporation) biweekly in an ongoing open-label extension study. Evidence of long-term efficacy, even in patients who developed IgG antibodies against rh- alpha GalA, included the continuously normal mean plasma globotriaosylceramide (GL-3) levels during 30 mo of the extension study and the sustained capillary endothelial GL-3 clearance in 98% (39/40) of patients who had a skin biopsy taken after treatment for 30 mo (original placebo group) or 36 mo (original enzyme-treated group). The mean serum creatinine level and estimated glomerular filtration rate also remained stable after 30-36 mo of treatment. Infusion-associated reactions decreased over time, as did anti-rh- alpha GalA IgG antibody titers. Among seroconverted patients, after 30-36 mo of treatment, seven patients tolerized (no detectable IgG antibody), and 59% had > or =4-fold reductions in antibody titers. As of 30 mo into the extension trial, three patients were withdrawn from the study because of positive serum IgE or skin tests; however, all have been rechallenged successfully at the time of this report. Thus, enzyme replacement therapy for 30-36 mo with agalsidase beta resulted in continuously decreased plasma GL-3 levels, sustained endothelial GL-3 clearance, stable kidney function, and a favorable safety profile.     

An International Bioinformatics Infrastructure to Underpin the Arabidopsis Community

The future bioinformatics needs of the Arabidopsis community as well as those of other scientific communities that depend on Arabidopsis resources were discussed at a pair of recent meetings held by the Multinational Arabidopsis Steering Committee and the North American Arabidopsis Steering Committee. There are extensive tools and resources for information storage, curation, and retrieval of Arabidopsis data that have been developed over recent years primarily through the activities of The Arabidopsis Information Resource, the Nottingham Arabidopsis Stock Centre, and the Arabidopsis Biological Resource Center, among others. However, the rapid expansion in many data types, the international basis of the Arabidopsis community, and changing priorities of the funding agencies all suggest the need for changes in the way informatics infrastructure is developed and maintained. We propose that there is a need for a single core resource that is integrated into a larger international consortium of investigators. We envision this to consist of a distributed system of data, tools, and resources, accessed via a single information portal and funded by a variety of sources, under shared international management of an International Arabidopsis Informatics Consortium (IAIC). This article outlines the proposal for the development, management, operations, and continued funding for the IAIC.The Multinational Arabidopsis Steering Committee (MASC) and the North American Arabidopsis Steering Committee (NAASC) hosted workshops in Nottingham, UK (April 15 to 16, 2010) and Washington DC (May 10 to 11, 2010) to consider the future bioinformatics needs of the Arabidopsis community as well as other science communities that depend vitally on Arabidopsis resources. The outcomes of both workshops were presented and discussed at the International Conference on Arabidopsis Research (ICAR) in Yokohama, Japan. The focus of the workshops was on Arabidopsis because of its unique and essential role as a reference organism for all seed plant species. The development of the highly annotated “gold standard” Arabidopsis genome sequence has been an invaluable resource for plant and crop sciences. This platform provides important information and working practices for other species and for comparative genomic and evolutionary studies. Arabidopsis tools and resources for information storage, curation, and retrieval have been developed over recent years primarily through the activities of The Arabidopsis Information Resource (TAIR), the Nottingham Arabidopsis Stock Centre (NASC), and the Arabidopsis Biological Resource Center, among others. However, the Arabidopsis community and funding agencies recognize the need for a single data management infrastructure. The key challenge is to develop and fund this resource in a sustainable and transparent manner.Global challenges surrounding food and energy security require intelligent plant breeding strategies that will be dependent on a central Arabidopsis information resource to aid our understanding of gene function and associated phenotype in many different environments. The knowledge accrued in Arabidopsis informs our understanding of the genetic basis of plant processes and crop traits. To date, this has accumulated primarily through analysis of single genes. However, gene products do not act alone but rather in complex interacting networks. Thus, the challenge for the Arabidopsis community is to understand this higher level of complexity, to a significant extent through the application of new high volume, quantitative experimental techniques. The goals of these efforts are to develop gene/protein/metabolite networks that will enable systems-level modeling of plant processes and ultimately to translate these findings to crop plants. To achieve these goals, we must develop novel approaches to data management, integration, and access.The UK workshop addressed three principal issues: the types of data generated by the Arabidopsis community, the types of data used by the community, and future needs of the community. The objective was to produce recommendations for the type of infrastructure necessary to address the challenges and opportunities associated with the application of new technologies and recommendations for a sustainable funding model to support this infrastructure. These recommendations were considered and expanded upon at the US workshop with the ultimate goal of generating solutions to the issues discussed in the first meeting. It was recognized that cohesive, cooperative, and long-term international collaboration will be critical to successfully maintain an Arabidopsis database infrastructure that is essential for plant biology research worldwide.The workshop participants concluded that there is a continued need for a central Arabidopsis information resource, based on the productivity of the Arabidopsis community and the critical importance of the findings generated by this community. For example, ∼3000 Arabidopsis publications are currently published in peer-reviewed journals each year, a nearly 10-fold increase since the early 1990s; and in 2009, TAIR was accessed by 335,692 unique visitors and had nearly 20 million page views. Furthermore, the importance of a current, well-organized, and carefully curated Arabidopsis genome to researchers studying other plants, including crops, cannot be overstated. In the future, this resource should be part of a larger infrastructure that would be dynamic and responsive to new directions in plant biology research.     

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared

Background

The provision of highly active antiretroviral therapy (HAART) in resource-limited settings follows a public health approach, which is characterised by a limited number of regimens and the standardisation of clinical and laboratory monitoring. In industrialized countries doctors prescribe from the full range of available antiretroviral drugs, supported by resistance testing and frequent laboratory monitoring. We compared virologic response, changes to first-line regimens, and mortality in HIV-infected patients starting HAART in South Africa and Switzerland.

Methods and Findings

We analysed data from the Swiss HIV Cohort Study and two HAART programmes in townships of Cape Town, South Africa. We included treatment-naïve patients aged 16 y or older who had started treatment with at least three drugs since 2001, and excluded intravenous drug users. Data from a total of 2,348 patients from South Africa and 1,016 patients from the Swiss HIV Cohort Study were analysed. Median baseline CD4⁺ T cell counts were 80 cells/μl in South Africa and 204 cells/μl in Switzerland. In South Africa, patients started with one of four first-line regimens, which was subsequently changed in 514 patients (22%). In Switzerland, 36 first-line regimens were used initially, and these were changed in 539 patients (53%). In most patients HIV-1 RNA was suppressed to 500 copies/ml or less within one year: 96% (95% confidence interval [CI] 95%–97%) in South Africa and 96% (94%–97%) in Switzerland, and 26% (22%–29%) and 27% (24%–31%), respectively, developed viral rebound within two years. Mortality was higher in South Africa than in Switzerland during the first months of HAART: adjusted hazard ratios were 5.90 (95% CI 1.81–19.2) during months 1–3 and 1.77 (0.90–3.50) during months 4–24.

Conclusions

Compared to the highly individualised approach in Switzerland, programmatic HAART in South Africa resulted in similar virologic outcomes, with relatively few changes to initial regimens. Further innovation and resources are required in South Africa to both achieve more timely access to HAART and improve the prognosis of patients who start HAART with advanced disease.